相关实验视频
Updated: Jun 11, 2025
00:03
Measurement of Chitinase Activity in Biological Samples
Published on: August 22, 2019
10.2K
基因酶1:在与代谢功能障碍相关的脂肪肝炎中是一种新的治疗标
Jung Hoon Cha1, Na Ri Park1, Sung Woo Cho1
1The Catholic University Liver Research Center, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Frontiers in immunology
|October 9, 2024
概括
基因酶1 (CHIT1) 在代谢功能障碍相关的脂肪肝炎 (MASH) 中驱动炎症和纤维化. 用OATD-01抑制CHIT1减少了肝损伤和纤维化,突出显示CHIT1是MASH的潜在治疗标.
科学领域:
- 肝病学和免疫学 肝病学和免疫学
- 分子和细胞生物学分子和细胞生物学
- 药物发现和开发 药物发现和开发
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 涉及由巨细胞激活驱动的持续性炎症.
- 激活的巨细胞产生的基因酶1 (CHIT1),与MASH病变和肝纤维化有关.
- 了解CHIT1的作用对于开发有针对性的MASH疗法至关重要.
研究的目的:
- 调查基因酶1 (CHIT1) 在代谢功能障碍相关的脂肪肝炎 (MASH) 与进展性肝纤维化中的作用.
- 在MASH小鼠模型中评估CHIT1抑制剂OATD-01的治疗潜力.
主要方法:
- 分析使用nCounter MAX,流细胞计,免疫组织化学和ELISA的患者的纤维化肝脏组织和血清.
- 构建一个MASH小鼠模型来评估OATD-01的疗效.
- 通过单核RNA测序和流细胞测量进行巨细胞分析.
主要成果:
- 在MASH患者中,CHIT1表达与肝纤维化,巨细胞透和炎症严重程度有很强的相关性.
- 在小鼠中,OATD-01治疗显著降低了MASH活性,肝纤维化以及关键的炎症和亲纤维性标志物.
- 用CHIT1抑制剂治疗降低了巨细胞的激活和透,特别是针对脂质相关巨细胞.
结论:
- 在MASH的炎症和纤维化过程中,CHIT1起着至关重要的作用.
- 抑制CHIT1显示出治疗进展性肝纤维化MASH的显著潜力.
- OATD-01代表了MASH的有希望的治疗候选者,特别是在更高的剂量下.
相关概念视频
01:24Chronic Pancreatitis I: Introduction
75
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
75
01:29Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301